"ID.number","Author","Year","Journal","Title","Primary.outcome","Primary.outcome.units","primary.analysis","ITT.based.on.assignment.alone","mITT.drug.at.least.once","mITT.exclude.based.on.exclusion.criteria","mITT.other.exclusion","PP.definition.clear","PP.exclude.concomitant.therapy","PP.exclude.incompliance","PP.exclude.missing.at.follow.up","PP.exclude.withdrawn.other.reasons","PP.exclude.other.reasons","itt.mitt.treatment.N","itt.mitt.treatment.success.N","treatment.itt.pp.ratio","control.itt.pp.ratio","PP.Treatment.N","PP.Treatment.Success.N","itt.mitt.control.N","itt.mitt.control.success.N","PP.Control.N","PP.Control.Success.N","planned.ci","NIM.margin","reported.itt.outcome","reported.itt.lower.CI","reported.itt.upper.CI","reported.pp.outcome","reported.pp.lower.CI","reported.pp.upper.CI","Adjust.missing.data","Missing.as.failure","Missing.tipping.point","Missing.multiple.imputation","Missing.last.outcome.carried.forward","Random.sequence.generation","Allocation.concealment","Performance.bias","Detection.bias","Attrition.bias","Reporting.bias"
100,"Moussaui",2006,"british medical journal","Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study","clinical cure","percentage",NA,1,0,0,0,1,0,1,1,0,0,56,50,0.964285714285714,0.952380952380952,54,50,63,56,60,56,"two sided 95%",10,0.4,-11,12,0.1,-9,10,1,1,0,0,0,"low risk","unclear","low risk","low risk","low risk","low risk"
101,"Fabian",2005,"surgical infections","Meropenem Versus Imipenem-Cilastatin for the Treatment of Hospitalized Patients with Complicated Skin and Skin Structure Infections: Results of a Multicenter, Randomized, Double-Blind Comparative Study","clinical response","percentage","both",0,1,1,0,1,1,1,1,0,0,510,244,0.511764705882353,0.544592030360531,261,225,527,268,287,238,"two sided 95%",10,-3.8,-9.8,2.1,3.3,-2.8,9.3,1,1,0,0,0,"unclear","low risk","low risk","low risk","high risk","low risk"
103,"Siquier",2006,"journal of antimicrobial chemotherapy","Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae","clinical success","percentage","PP",0,1,0,0,0,1,0,0,0,0,374,313,0.770053475935829,0.770833333333333,288,266,192,158,148,135,"two sided 95%",10,1.4,-5.2,8,1.1,-4.4,6.6,1,1,0,0,0,"unclear","unclear","unclear","unclear","low risk","low risk"
105,"Corey",2010,"journal of antimicrobial chemotherapy","CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","clinical cure","percentage","both",0,1,0,1,1,1,1,0,0,0,351,304,0.9002849002849,0.864553314121037,316,288,347,297,300,280,"two sided 95%",10,1,-4.2,6.2,-2.2,-6.6,2.1,0,0,0,0,0,"low risk","low risk","unclear","unclear","low risk","low risk"
106,"Wilcox",2010,"journal of antimicrobial chemotherapy","CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","clinical cure","percentage","both",0,1,0,1,1,1,1,0,0,0,342,291,0.859649122807018,0.863905325443787,294,271,338,289,292,269,"two sided 95%",10,-0.4,-5.8,5,0.1,-4.4,4.5,0,0,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
108,"File",2007,"journal of antimicrobial chemotherapy","Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study","clinical success","percentage","both",0,1,0,0,1,0,1,1,0,0,256,237,0.9453125,0.893700787401575,242,230,254,221,227,209,"two sided 95%",10,5.6,0.34,10.81,-2.9,-1.48,7.42,0,0,0,0,0,"unclear","unclear","low risk","low risk","low risk","low risk"
109,"File",2011,"journal of antimicrobial chemotherapy","FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","clnical cure","percentage","both",0,1,0,0,0,0,0,1,0,0,291,244,0.769759450171821,0.78,224,194,300,233,234,183,"two sided 95%",10,6.2,-0.2,12.6,8.4,1.4,15.4,0,0,0,0,0,"low risk","low risk","low risk","low risk","unclear","low risk"
11,"Rudrabhatia",2018,"plos one","Stopping the effective non-fluoroquinolone antibiotics at day 7 vs continuing until day 14 in adults with acute pyelonephritis requiring hospitalization: A randomized non-inferiority trial","recurrence","percentage","ITT.or.mITT",1,0,0,0,1,0,0,1,0,0,27,27,0.962962962962963,1,26,26,27,26,27,26,"two sided 90%",15,3.7,-6.15,15.01,3.85,-6.04,15.53,0,0,0,0,0,"high risk","unclear","high risk","high risk","low risk","low risk"
110,"Low",2011,"journal of antimicrobial chemotherapy","FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","clinical cure","percentage","both",0,1,0,0,0,0,0,1,0,0,289,235,0.813148788927336,0.787545787545788,235,193,273,206,215,166,"two sided 95%",10,5.9,-1,12.7,4.9,-2.5,12.5,0,0,0,0,0,"low risk","low risk","low risk","low risk","unclear","low risk"
111,"Huang",2018,"clinical infectious diseases","A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1","early clinical response","percentage","ITT.or.mITT",1,0,0,0,0,0,0,1,1,0,298,241,0.899328859060403,0.94,268,228,300,243,282,232,"two sided 95%",10,-0.13,-6.42,6.17,-1.49,-7.44,4.46,1,1,0,0,0,"unclear","unclear","low risk","low risk","high risk","low risk"
115,"Corey",2014,"new england journal of medicine","Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections","early clinical response","percentage","ITT.or.mITT",0,1,0,0,1,1,1,1,0,0,475,391,0.829473684210526,0.828810020876827,394,344,479,378,397,342,"two sided 95%",10,3.4,-1.6,8.4,1.2,-3.6,5.9,1,1,0,0,0,"unclear","unclear","low risk","low risk","low risk","low risk"
117,"Stets",2019,"new england journal of medicine","Omadacycline for Community-Acquired Bacterial Pneumonia","early clinical response","percentage","ITT.or.mITT",1,0,0,0,1,1,0,1,0,0,386,313,0.922279792746114,0.927835051546392,356,308,388,321,360,314,"two sided 95%",10,-1.6,-7.1,3.8,-0.7,-5.7,4.3,1,1,0,0,0,"low risk","low risk","low risk","low risk","unclear","low risk"
118,"O'Riordan",2019,"lancet infectious diseases","Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial","early clinical response","percentage","ITT.or.mITT",0,0,1,0,1,1,1,1,0,0,360,315,0.936111111111111,1,337,315,360,297,360,297,"two sided 95%",10,5,-0.2,10.3,2.1,-2,6.3,1,1,1,1,0,"low risk","low risk","low risk","low risk","low risk","low risk"
120,"Federico",2012,"gastroenterology","Efficacy of 5-Day Levofloxacin-Containing Concomitant Therapy in Eradication of Helicobacter pylori Infection","eradication","percentage","both",1,0,0,0,1,0,0,1,0,0,90,83,0.955555555555556,0.977777777777778,86,83,90,84,88,84,"two sided 95%",10,1.1,-7.6,9.8,-1,-8,5.9,0,0,0,0,0,"low risk","low risk","high risk","low risk","low risk","low risk"
121,"Freire",2010,"diagnostic microbiology and infectious disease","Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia","clinical response","percentage","both",0,1,1,0,1,1,1,1,0,0,440,276,0.609090909090909,0.566433566433566,268,182,429,290,243,190,"two sided 95%",15,-4.8,-11,1.3,-10.4,-17.8,-3,0,0,0,0,0,"unclear","unclear","high risk","low risk","high risk","low risk"
122,"Lauf",2014,"diagnostic microbiology and infectious disease","Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis","clinical response","percentage","both",0,1,1,0,1,1,1,1,0,0,476,340,0.857142857142857,0.869098712446352,408,316,466,363,405,334,"two sided 95%",10,-6.7,-12.3,-1.1,-5.5,-11,0.1,0,0,0,0,0,"low risk","low risk","low risk","low risk","high risk","low risk"
123,"Dartois",2008,"journal of chemotherapy","Tigecycline Versus Levofloxacin for the Treatment of Community-Acquired Pneumonia: European Experience","clinical response","percentage","both",0,1,1,0,0,1,0,1,0,0,173,146,0.722543352601156,0.69364161849711,125,112,173,142,120,103,"two sided 95%",15,2.3,-6.1,10.8,3.8,-5.3,12.8,0,0,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
124,"Bergallo",2009,"diagnostic microbiology and infectious disease","Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin","clinical response","percentage","both",0,1,1,0,1,1,1,1,0,0,191,149,0.722513089005236,0.768472906403941,138,125,203,158,156,136,"two sided 95%",15,0.2,-8.5,8.9,3.4,-4.4,11.2,0,0,0,0,0,"unclear","unclear","high risk","low risk","high risk","low risk"
125,"Sacchidanad",2005,"international journal of infectious diseases","Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial","clinical response","percentage","both",0,1,1,0,1,1,0,1,0,1,277,209,0.71841155234657,0.761538461538461,199,165,260,200,198,163,"two sided 95%",15,-1.5,-9,6.1,0.6,-7.4,8.6,0,0,0,0,0,"unclear","unclear","low risk","low risk","high risk","low risk"
126,"Louie",2011,"new england journal of medicine","Fidaxomicin versus Vancomycin for Clostridium difficile Infection","clinical cure","percentage","both",0,1,1,0,1,1,1,1,0,0,287,253,0.923344947735192,0.915857605177994,265,244,309,265,283,254,"one sided 97.5%",10,2.4,-3.1,NA,2.3,-2.6,NA,0,0,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
127,"Solomkin",2015,"clinical infectious diseases","Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)","clinical cure","percentage","ITT.or.mITT",0,0,0,0,1,1,1,1,0,0,389,323,0.70694087403599,0.76978417266187,275,259,417,364,321,304,"two sided 95%",10,-4.2,-8.91,0.54,-1,-4.52,2.59,1,1,0,0,0,"low risk","unclear","low risk","low risk","high risk","low risk"
129,"Weiss",2009,"journal of chemotherapy","Moxifloxacin for the Treatment of Patients with Complicated Intra-abdominal Infections (the AIDA Study)","clinical success","percentage","PP",0,1,0,0,1,1,1,1,0,0,289,207,0.85121107266436,0.898305084745763,246,199,295,227,265,218,"two sided 95%",10,-5.3,-12.4,1.5,-1.4,-8.9,4.2,1,1,0,0,0,"low risk","unclear","high risk","high risk","low risk","low risk"
13,"Bernard",2015,"lancet","Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial","clinical cure","percentage",NA,0,1,1,1,1,1,1,0,0,0,176,160,0.829545454545455,0.782857142857143,146,137,175,159,137,132,"two sided 95%",10,0.05,-6.2,6.3,-2.5,-8.2,2.9,1,1,0,0,0,"low risk","low risk","high risk","low risk","low risk","low risk"
130,"Molina",2013,"gastroenterology","Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance","eradication","percentage","ITT.or.mITT",1,0,0,0,1,0,1,0,0,0,170,153,0.958823529411765,0.917647058823529,163,150,170,156,156,150,"two sided 95%",8,-1.7,NA,NA,-1.1,NA,NA,1,1,0,0,0,"low risk","low risk","high risk","high risk","low risk","high risk"
131,"Mazuski",2016,"clinical infectious diseases","Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program","clinical cure","percentage",NA,0,1,0,0,1,1,1,1,0,1,520,429,0.788461538461538,0.795411089866157,410,376,523,444,416,385,"two sided 95%",12.5,-2.4,-6.9,2.1,-0.8,-4.61,2.89,0,0,0,0,0,"unclear","unclear","low risk","low risk","low risk","low risk"
132,"Chung",2011,"helicobacter","Second-line Helicobacter pylori Eradication: A Randomized Comparison of 1-week or 2-week Bismuth-containing Quadruple Therapy","eradication","percentage","both",1,0,0,0,1,0,1,1,1,0,98,80,0.887755102040816,0.792079207920792,87,78,101,86,80,77,"one sided 97.5%",15,NA,NA,NA,NA,NA,NA,1,1,0,0,0,"low risk","low risk","unclear","unclear","low risk","high risk"
133,"Dore",2011,"helicobacter","Twice-a-Day Bismuth-Containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Trial of 10 and 14 Days","eradication","percentage","both",1,0,0,0,1,0,0,1,1,0,215,199,0.972093023255814,0.95049504950495,209,199,202,185,192,185,"two sided 95%",10,NA,NA,NA,1,NA,NA,0,0,0,0,0,"low risk","low risk","high risk","high risk","low risk","high risk"
134,"Tsay",2015,"helicobacter","Reverse Sequential Therapy Achieves a Similar Eradication Rate as Standard Sequential Therapy for Helicobacter pylori Eradication: A Randomized Controlled Trial","eradication","percentage","both",0,1,0,0,1,0,1,1,0,0,60,58,1,0.983870967741935,60,58,62,57,61,56,"two sided 95%",10,-4.8,NA,NA,-4.9,NA,NA,1,1,0,0,0,"low risk","unclear","high risk","high risk","low risk","high risk"
135,"Bohbot",2010,"infectious diseases in obstetrics and gynecology","Treatment of Bacterial Vaginosis: A Multicenter, Double-Blind, Double-Dummy, Randomised Phase III Study Comparing Secnidazole andMetronidazole","therapeutic success","percentage","ITT.or.mITT",0,1,1,0,1,1,1,1,0,0,290,169,0.744827586206897,0.70383275261324,216,137,287,166,202,127,"two sided 95%",10,0.5,-7.6,8.5,0.5,-8.7,9.8,1,1,0,0,0,"low risk","unclear","low risk","low risk","low risk","low risk"
136,"Jindani",2014,"new england journal of medicine","High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis","unfavourable outcome","percentage","both",0,0,1,1,1,0,1,0,0,0,193,141,0.854922279792746,0.867021276595745,165,135,188,161,163,155,"two sided 90%",6,-13.1,-19.4,6.8,-13.6,-19.1,8.1,0,0,0,0,0,"low risk","unclear","high risk","high risk","high risk","low risk"
136,"Jindani",2014,"new england journal of medicine","High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis","unfavourable outcome","percentage","both",0,0,1,1,1,0,1,0,0,0,212,183,0.877358490566038,0.867021276595745,186,180,188,161,163,155,"two sided 90%",6,0.4,-5.6,4.7,1.8,-2.4,6.1,0,0,0,0,0,"low risk","unclear","high risk","high risk","high risk","low risk"
14,"Cornely",2012,"lancet infectious diseases","Fidaxomicin versus vancomycin for infection with Clostridium diffi cile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","clinical cure","percentage","both",0,1,1,1,1,1,1,0,0,0,252,221,0.857142857142857,0.914396887159533,216,198,257,223,235,213,"one sided 97.5%",10,0.9,-4.9,6.7,1.1,-4.3,NA,0,0,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
141,"Lienhardt",2011,"jama","Efficacy and Safety of a 4-Drug Fixed-Dose Combination Regimen Compared With Separate Drugs for Treatment of Pulmonary Tuberculosis","favorable outcome","percentage","both",0,1,1,0,1,1,1,0,0,0,684,570,0.864035087719298,0.871987951807229,591,555,664,563,579,548,"two sided 90%",4,-1.5,-4.7,1.8,-0.7,-3,1.5,1,1,0,0,0,"low risk","low risk","high risk","high risk","high risk","low risk"
142,"Merle",2014,"new england journal of medicine","A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis","unfavorable outcome","percentage","both",0,1,1,1,1,0,1,0,0,0,694,548,0.938040345821326,0.90785498489426,651,536,662,548,601,533,"two sided 95%",6,-3.5,-7.7,0.7,-5.5,-9.4,-1.6,0,0,0,0,0,"low risk","low risk","high risk","high risk","high risk","high risk"
143,"Gillespie",2014,"new england journal of medicine","Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis","unfavorable outcome","percentage","PP",0,0,1,1,1,0,1,1,0,0,568,436,0.904929577464789,0.918918918918919,514,436,555,468,510,467,"two sided 97.5%",6,-7.8,-13,2.7,-6.1,-10.5,1.7,0,0,0,0,0,"low risk","unclear","low risk","low risk","high risk","low risk"
143,"Gillespie",2014,"new england journal of medicine","Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis","unfavorable outcome","percentage","PP",0,0,1,1,1,0,1,1,0,0,551,419,0.950998185117967,0.918918918918919,524,419,555,468,510,467,"two sided 97.5%",6,-9,-14.2,3.8,-11.4,-16.1,-6.7,0,0,0,0,0,"low risk","unclear","low risk","low risk","high risk","low risk"
144,"Nunn",2019,"new england journal of medicine","A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis","favorable outcome","percentage","both",0,0,1,1,1,0,1,1,0,1,245,193,0.926530612244898,0.669354838709677,227,186,124,99,83,67,"two sided 95%",10,-1,-9.5,7.5,0.7,-9.1,10.5,0,0,0,0,0,"unclear","unclear","high risk","high risk","high risk","low risk"
147,"Kaye",2018,"jama","Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection The TANGO I Randomized Clinical Trial","composite cure","percentage","ITT.or.mITT",0,1,0,1,1,0,1,1,0,0,192,128,0.927083333333333,0.928571428571429,178,118,182,105,169,102,"two sided 95%",15,4.5,0.7,9.1,NA,NA,NA,1,0,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
149,"File",2004,"antimicrobial agents and chemotherapy","Double-Blind, Randomized Study of the Efficacy and Safety of Oral Pharmacokinetically Enhanced Amoxicillin-Clavulanate (2,000/125 Milligrams) versus Those of Amoxicillin-Clavulanate (875/125 Milligrams), Both Given Twice Daily for 7 Days, in Treatment of Bacterial Community-Acquired Pneumonia in Adults","clinical response","percentage","PP",0,1,0,0,0,1,0,1,0,0,322,274,0.767080745341615,0.726688102893891,247,223,311,243,226,198,"two sided 95%",10,7,0.9,13,2.7,-3,8.3,1,1,0,0,0,"unclear","unclear","low risk","low risk","low risk","low risk"
15,"Mitja",2012,"lancet","Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomised trial","serologic and clinical cure","percentage","PP",1,0,0,0,1,0,0,1,1,0,124,106,0.887096774193548,0.896825396825397,110,106,126,105,113,105,"two sided 95%",10,2.2,-6.8,11.1,3.4,-2.4,9.3,1,1,0,0,0,"low risk","low risk","high risk","high risk","low risk","low risk"
151,"Rensburg",2010,"antimicrobial agents and chemotherapy","Efficacy and Safety of Nemonoxacin versus Levofloxacin for Community-Acquired Pneumonia","clinical response","percentage","ITT.or.mITT",0,1,0,0,0,0,1,0,0,0,89,67,0.921348314606742,0.877777777777778,82,64,90,72,79,65,"two sided 97.5%",15,-4.7,-18.6,9.1,-4.3,-18.7,9.1,0,0,0,0,0,"unclear","unclear","low risk","low risk","unclear","low risk"
151,"Rensburg",2010,"antimicrobial agents and chemotherapy","Efficacy and Safety of Nemonoxacin versus Levofloxacin for Community-Acquired Pneumonia","clinical response","percentage","ITT.or.mITT",0,1,0,0,0,0,1,0,0,0,86,71,0.918604651162791,0.877777777777778,79,66,90,72,79,65,"two sided 97.5%",15,2.6,-10.5,15.7,1.2,-12.1,14.6,0,0,0,0,0,"unclear","unclear","low risk","low risk","unclear","low risk"
156,"Desrosiers",2008,"current medical research and opinion","Clinical efficacy and time to symptom resolution of 5-day telithromycin versus 10-day amoxicillin_clavulanate in the treatment of acute bacterial sinusitis","clinical success","percentage","PP",0,1,1,0,1,1,1,1,0,0,144,125,0.854166666666667,0.856164383561644,123,109,146,128,125,111,"two sided 95%",15,-0.9,-9.2,7.5,-0.2,-8.9,8.5,0,0,0,0,0,"low risk","unclear","high risk","high risk","low risk","low risk"
158,"Lucasti",2008,"clinical therapeutics","Efficacy and Tolerability of IV Doripenem Versus Meropenem in Adults with Complicated Intra-Abdominal Infection: A Phase III, Prospective, Multicenter, Randomized, Double-Blind, Noninferiority Study","clinical response","percentage","both",0,1,1,1,1,1,1,1,0,1,195,152,0.835897435897436,0.821052631578947,163,140,190,150,156,133,"two sided 95%",15,-1,-9.7,7.7,0.6,-7.7,9,0,0,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
162,"Corey",2015,"clinical infectious diseases","Single-Dose Oritavancin Versus 7_10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study","early clinical response","percentage","ITT.or.mITT",0,1,0,0,1,0,1,1,0,0,503,403,0.848906560636183,0.812749003984064,427,357,502,416,408,358,"two sided 95%",10,-2.7,-7.5,2,-4.1,-8.9,6,1,1,0,0,0,"unclear","unclear","low risk","low risk","low risk","low risk"
163,"Clegg",2006,"pediatric infectious diseases journal","Treatment of Streptococcal Pharyngitis With Once-Daily Compared With Twice-Daily Amoxicillin A Noninferiority Trial","bacteriologic failure","percentage","PP",1,0,0,0,1,0,0,1,0,0,326,218,0.901840490797546,0.907975460122699,294,235,326,217,296,250,"two sided 90%",10,0.3,-5.8,6.4,-4.53,-9.7,0.6,1,1,0,0,0,"low risk","unclear","high risk","low risk","low risk","low risk"
165,"Zanetti",2003,"antimicrobial agents and chemotherapy","Cefepime versus Imipenem-Cilastatin for Treatment of Nosocomial Pneumonia in Intensive Care Unit Patients: a Multicenter, Evaluator-Blind, Prospective, Randomized Study","clinical response","percentage","PP",0,0,1,1,1,1,1,1,0,0,132,78,0.818181818181818,0.731884057971015,108,76,138,78,101,75,"two sided 95%",15,2,-9,14,-4,-16,8,1,1,0,0,0,"low risk","low risk","high risk","low risk","low risk","low risk"
169,"Rimoin",2011,"clinical pediatrics","Treatment of Streptococcal Pharyngitis With Once-Daily Amoxicillin Versus Intramuscular Benzathine Penicillin G in Low-Resource Settings: A Randomized Controlled Trial","bacteriologic eradication","percentage",NA,1,0,0,0,1,0,1,1,0,0,124,94,1,0.300813008130081,124,94,123,76,37,25,"two sided 95%",10,-15.1,-26.6,-3.4,-9.3,-26.3,7.8,0,0,0,0,0,"low risk","low risk","high risk","high risk","high risk","low risk"
169,"Rimoin",2011,"clinical pediatrics","Treatment of Streptococcal Pharyngitis With Once-Daily Amoxicillin Versus Intramuscular Benzathine Penicillin G in Low-Resource Settings: A Randomized Controlled Trial","bacteriologic eradication","percentage",NA,1,0,0,0,1,0,1,1,0,0,57,38,1,0.84375,57,38,64,45,54,37,"two sided 95%",10,2.5,-13.8,18.9,1.1,-16.2,18.5,0,0,0,0,0,"low risk","low risk","high risk","high risk","high risk","low risk"
17,"Mikamo",2018,"journal of infection and chemotherapy","Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan","global cure","percentage","ITT.or.mITT",0,1,0,0,1,1,1,1,0,0,104,70,0.817307692307692,0.87962962962963,85,63,108,71,95,66,"two sided 95%",10,1.2,-11.3,13.7,3.9,-9.1,16.8,1,1,0,0,0,"low risk","unclear","low risk","low risk","high risk","low risk"
170,"Uranga",2016,"jama internal medicine","Duration of Antibiotic Treatment in Community-Acquired Pneumonia A Multicenter Randomized Clinical Trial","clinical cure","percentage","both",1,0,0,0,1,0,1,1,0,0,162,147,0.901234567901235,0.913333333333333,146,136,150,132,137,126,"not used",3,NA,NA,NA,NA,NA,NA,0,0,0,0,0,"low risk","unclear","high risk","high risk","low risk","high risk"
170,"Uranga",2016,"jama internal medicine","Duration of Antibiotic Treatment in Community-Acquired Pneumonia A Multicenter Randomized Clinical Trial","clinical cure","percentage","both",1,0,0,0,1,0,1,1,0,0,162,90,0.901234567901235,0.913333333333333,146,86,150,71,137,67,"not used",3,NA,NA,NA,NA,NA,NA,0,0,0,0,0,"low risk","unclear","high risk","high risk","low risk","high risk"
172,"Li",2019,"new england journal of medicine","Oral versus Intravenous Antibiotics for Bone and Joint Infection","treatment failure","percentage","ITT.or.mITT",1,0,0,1,1,0,1,1,0,0,527,457,0.884250474383302,0.840607210626186,466,405,527,450,443,374,"two sided 90%",7.5,-1.4,-4.9,2.2,-2.5,-6.3,1.3,1,0,1,1,0,"low risk","unclear","high risk","low risk","low risk","low risk"
174,"Naber",2004,"infectious diseases in clinical practice","Daptomycin Versus Ciprofloxacin in the Treatment of Complicated Urinary Tract Infection Due to Gram-positive Bacteria","microbiologic efficacy","percentage",NA,0,1,1,0,0,0,1,1,0,1,29,24,1,0.928571428571429,29,24,28,22,26,22,"two sided 95%",10,4.2,-16.3,24.7,-1.8,-21.4,17.7,0,0,0,0,0,"unclear","low risk","high risk","high risk","low risk","high risk"
176,"Noel",2008,"antimicrobial agents and chemotherapy","Results of a Double-Blind, Randomized Trial of Ceftobiprole Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria","clinical cure","percentage",NA,1,0,0,1,1,0,0,1,0,1,397,309,0.710327455919396,0.715762273901809,282,263,387,300,277,259,"two sided 95%",10,0.3,-5.5,6.1,-0.2,-4.4,3.9,0,0,0,0,0,"low risk","unclear","low risk","low risk","low risk","low risk"
177,"UpChurch",2006,"otolaryngology head and neck surgery","Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitis","clinical response","percentage","both",1,0,0,0,1,0,1,1,1,0,366,262,0.806010928961749,0.772972972972973,295,237,370,250,286,213,"two sided 95%",10,4,-2.7,10.5,5.8,0.1,13.6,1,1,0,0,0,"low risk","unclear","low risk","low risk","low risk","low risk"
177,"UpChurch",2006,"otolaryngology head and neck surgery","Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitis","clinical response","percentage","both",1,0,0,0,1,0,1,1,1,0,363,255,0.771349862258953,0.772972972972973,280,229,370,250,286,213,"two sided 95%",10,2.6,-3.9,9.5,7.3,1.7,15.2,1,1,0,0,0,"low risk","unclear","low risk","low risk","low risk","low risk"
178,"O'Riordan",2018,"clinical infectious diseases","A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study","early clinical response","percentage","ITT.or.mITT",1,0,0,0,1,1,1,0,0,0,423,354,0.933806146572104,0.90632318501171,395,346,427,344,387,327,"two sided 95%",10,3.1,-2,8.3,3.1,-1.8,8,1,1,0,0,0,"unclear","unclear","low risk","low risk","low risk","low risk"
180,"Chastre",2008,"critical care medicine","Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study","clinical cure","percentage","both",0,1,0,0,1,1,1,1,0,0,249,147,0.506024096385542,0.484126984126984,126,86,252,146,122,79,"two sided 95%",20,1.2,-7.9,10.3,3.5,-9.1,16.1,0,0,0,0,0,"unclear","unclear","high risk","high risk","low risk","low risk"
183,"Leroy",2005,"chest","Comparison of Levofloxacin and Cefotaxime Combined With Ofloxacin for ICU Patients With Community-Acquired Pneumonia Who Do Not Require Vasopressors","clinical response","percentage","PP",0,1,1,0,1,1,1,1,1,0,149,112,0.932885906040268,0.830188679245283,139,110,159,123,132,105,"two sided 95%",15,-2.2,-12.35,7.97,-0.4,-10.79,9.97,1,1,0,0,0,"low risk","unclear","high risk","high risk","low risk","low risk"
184,"Torres",2008,"clinical infectious diseases","Moxifloxacin Monotherapy Is Effective in Hospitalized Patients with Community-Acquired Pneumonia: The MOTIV Study�A Randomized Clinical Trial","clinical response","percentage","PP",0,1,0,0,1,1,1,1,1,0,368,293,0.790760869565217,0.761643835616438,291,253,365,306,278,250,"two sided 95%",10,-4.2,-9.7,1.4,-3,-8.1,2.2,1,1,0,0,0,"low risk","unclear","low risk","low risk","low risk","low risk"
187,"Agweyu",2015,"clinical infectious diseases","Oral Amoxicillin Versus Benzyl Penicillin for Severe Pneumonia Among Kenyan Children: A Pragmatic Randomized Controlled Noninferiority Trial","treatment failure","percentage","both",1,0,0,0,1,0,1,0,0,0,263,243,0.988593155893536,0.992395437262357,260,240,263,242,261,240,"two sided 95%",7,0.4,-4.2,5,0.3,-4.3,5,0,0,0,0,0,"low risk","low risk","high risk","high risk","low risk","low risk"
188,"Lojanapiwat",2019,"infection and drug resistance","Oral sitafloxacin vs intravenous ceftriaxone followed by oral cefdinir for acute pyelonephritis and complicated urinary tract infection: a randomized controlled trial","clinical success","percentage","both",0,1,1,1,1,1,1,1,1,1,141,122,0.765957446808511,0.695945945945946,108,105,148,124,103,102,"two sided 95%",15,2.8,-4.2,9.7,-1.8,-5.9,1.9,0,0,0,0,0,"unclear","unclear","high risk","high risk","low risk","low risk"
19,"Snyman",2009,"clinical drug investigation","Generic versus non-generic formulation of extended-release clarithromycin in patients with community acquired respiratory tract infection","clinical cure","percentage",NA,0,1,0,0,0,0,0,1,1,1,121,114,0.991735537190083,0.983606557377049,120,113,122,117,120,115,"one sided 95%",10,NA,NA,NA,-1.6,NA,NA,0,0,0,0,0,"low risk","unclear","low risk","high risk","low risk","high risk"
190,"Iversen",2019,"new england journal of medicine","Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis","composite mortality, surgery, embolic event, bacteremia","percentage","ITT.or.mITT",1,0,0,0,0,0,1,0,0,0,201,183,0.980099502487562,1,197,179,199,175,199,175,"one sided 97.5%",10,3.1,-3.4,9.6,3,-3.2,9.2,0,0,0,0,0,"low risk","low risk","high risk","high risk","low risk","low risk"
193,"Solomkin",2017,"jama surgery","Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial A Randomized Clinical Trial","clinical cure","percentage","ITT.or.mITT",0,1,0,0,0,0,0,0,0,0,270,235,0.885185185185185,0.888059701492537,239,222,268,238,238,225,"two sided 95%",10,-1.8,-7.4,3.8,-1.7,-6.3,2.8,0,0,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
196,"Awad",2014,"clinical infectious diseases","A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia","clinical cure","percentage","both",1,0,0,0,1,1,1,1,0,1,391,195,0.641943734015345,0.625641025641026,251,174,390,206,244,174,"two sided 95%",15,-2.9,-10,4.1,-2,-10,6.1,0,0,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
198,"Bradley",2007,"pediatric infectious diseases journal","Comparative Study of Levofloxacin in the Treatment of Children With Community-Acquired Pneumonia","clinical cure","percentage","PP",0,1,1,0,1,1,1,1,0,0,503,439,0.805168986083499,0.788235294117647,405,382,170,145,134,126,"two sided 95%",10,2,-4.1,8.1,0.3,-4.3,4.9,0,0,0,0,0,"unclear","unclear","high risk","high risk","high risk","low risk"
2,"van Nieuwkoop",2017,"bmc medicine","Treatment duration of febrile urinary tract infection: a pragmatic randomized, doubleblind, placebo-controlled non-inferiority trial in men and women","clinical cure","percentage","ITT.or.mITT",0,1,0,0,1,1,1,0,1,0,94,85,0.978723404255319,0.929292929292929,92,83,99,94,92,87,"two sided 90%",10,-4.5,-10.7,1.7,-4.3,-10.8,2.1,0,0,0,0,0,"low risk","unclear","low risk","unclear","low risk","low risk"
200,"Klausner",2007,"current medical research and opinion","A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis","microbiologic eradication","percentage","both",0,1,1,0,1,1,1,1,0,1,94,78,0.851063829787234,0.775510204081633,80,74,98,78,76,71,"two sided 95%",15,3.4,-7.6,14.4,-0.9,-8.9,7.1,0,0,0,0,0,"low risk","low risk","low risk","low risk","high risk","low risk"
203,"Fowler",2006,"new england journal of medicine","Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus","clinical success","percentage","ITT.or.mITT",0,1,1,0,1,0,1,1,1,0,120,53,0.658333333333333,0.521739130434783,79,43,115,48,60,32,"two sided 95%",20,3.4,-8.9,15.7,1.1,-15.6,17.8,0,0,0,0,0,"low risk","unclear","high risk","high risk","low risk","low risk"
204,"Saar",2019,"journal of trauma and acute care surgery","Twenty-four hour versus extended antibiotic administration after surgery in complicated appendicitis: A randomized controlled trial","postoperative complications","percentage","both",1,0,0,0,1,0,1,0,0,0,39,32,0.82051282051282,1,32,25,41,29,41,29,"two sided 95%",NA,-11.4,NA,NA,-7.4,NA,NA,0,0,0,0,0,"low risk","unclear","high risk","high risk","low risk","high risk"
205,"Fourcory",2005,"antimicrobial agents and chemotherapy","Efficacy and Safety of a Novel Once-Daily Extended-Release Ciprofloxacin Tablet Formulation for Treatment of Uncomplicated Urinary Tract Infection in Women","microbiologic eradication","percentage","PP",0,0,1,0,1,1,0,1,0,0,293,254,0.928327645051195,0.936567164179104,272,254,268,225,251,225,"two sided 95%",10,2.7,-3.16,8.56,3.8,-0.99,8.59,0,0,0,0,0,"low risk","unclear","low risk","low risk","high risk","low risk"
206,"Hooton",2012,"jama","Cefpodoxime vs Ciprofloxacin for Short-Course Treatment of Acute Uncomplicated Cystitis: A Randomized Trial","clinical cure","percentage","ITT.or.mITT",1,0,0,0,1,0,0,1,0,0,150,106,0.886666666666667,0.9,133,106,150,124,135,124,"two sided 95%",10,-12,-21,-3,-12,-20,-4,1,1,0,0,0,"low risk","low risk","low risk","low risk","high risk","low risk"
207,"Noel",2008,"clinical infectious diseases","A Randomized, Double-Blind Trial Comparing Ceftobiprole Medocaril with Vancomycin plus Ceftazidime for the Treatment of Patients with Complicated Skin and Skin-Structure Infections","clinical cure","percentage","both",1,0,0,0,1,1,1,1,0,0,547,448,0.886654478976234,0.868327402135231,485,439,281,227,244,220,"two sided 95%",10,1.1,-4.5,6.7,0.3,-4.2,4.9,0,0,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
209,"Peterson",2008,"urology","A Double-Blind, Randomized Comparison of Levofloxacin 750 mg Once-Daily for Five Days With Ciprofloxacin 400/500 mg Twice-Daily for 10 Days for the Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis","microbiologic eradication","percentage","both",0,1,1,0,1,0,1,1,0,0,317,253,0.83596214511041,0.798013245033113,265,228,302,241,241,215,"two sided 95%",15,0,-6.3,6.3,3.2,-2.5,8.9,1,1,0,0,0,"low risk","low risk","low risk","low risk","high risk","low risk"
21,"Malfertheiner",2011,"lancet","Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial","eradication by urease test","percentage","PP",1,0,0,0,1,1,0,1,1,0,218,174,0.81651376146789,0.725225225225225,178,166,222,123,161,112,"two sided 95%",10,25,15.5,33.3,23,15.1,32.3,1,1,0,0,0,"low risk","unclear","high risk","low risk","low risk","low risk"
210,"English",2012,"antimicrobial agents and chemotherapy","Cethromycin versus Clarithromycin for Community-Acquired Pneumonia: Comparative Efficacy and Safety Outcomes from Two Double-Blinded, Randomized, Parallel-Group, Multicenter, Multinational Noninferiority Studies","clinical cure","percentage","both",0,1,0,0,1,1,1,1,1,0,518,430,0.853281853281853,0.846153846153846,442,410,507,430,429,407,"two sided 95%",15,-1.8,-6.4,2.8,-2.1,-5.4,1.2,1,1,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
213,"Rubinstein",2011,"clinical infectious diseases","Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens","clinical cure","percentage","both",0,1,0,0,1,1,0,1,0,1,749,441,0.416555407209613,0.453580901856764,312,257,754,449,342,276,"two sided 95%",20,-0.7,-5.6,4.3,1.7,-4.3,7.7,0,0,0,0,0,"low risk","low risk","low risk","low risk","high risk","high risk"
214,"Mir",2019,"open forum infectious diseases","Ceftriaxone+Sulbactam+Disodium EDTA Versus Meropenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: PLEA, a Double-Blind, Randomized Noninferiority Trial","clinical cure","percentage","ITT.or.mITT",0,1,1,1,1,1,1,1,0,1,74,71,0.972972972972973,0.985507246376812,72,71,69,62,68,62,"two sided 95%",10,6,-2.6,16,7.4,0.2,16.8,1,0,1,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
215,"Solomkin",2019,"clinical infectious diseases","IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections","clinical cure","percentage","ITT.or.mITT",0,1,1,1,1,1,1,1,0,1,195,177,0.892307692307692,0.946341463414634,174,167,205,187,194,187,"two sided 95%",12.5,-0.5,-6.3,5.3,-0.4,-4.9,3.8,0,0,0,0,0,"low risk","low risk","low risk","low risk","high risk","low risk"
218,"Chen",2018,"therapeutics and clinical risk management","A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China","clinical response","percentage","both",0,1,0,0,0,1,1,1,0,0,232,192,0.892241379310345,0.887445887445887,207,186,231,205,205,198,"two sided 95%",15,-6,-12.8,0.8,-6.7,-12,-1.4,0,0,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
22,"Barrera",2016,"lancet infectious diseases","Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)","early response based on symptoms and signs","percentage",NA,1,0,0,0,1,1,0,1,1,0,426,333,0.946009389671362,0.93778801843318,403,326,434,338,407,330,"two sided 95%",10,0.29,-5.5,6.1,-0.19,-5.8,5.5,0,0,0,0,0,"low risk","unclear","low risk","low risk","low risk","low risk"
220,"Sapmaz",2017,"american journal of therapeutics","A Non-Inferiority Study: Modified Dual Therapy Consisting Higher Doses of Rabeprazole Is as Successful as Standard Quadruple Therapy in Eradication of Helicobacter pylori","eradication rate","percentage","both",0,0,0,1,1,0,1,0,0,0,98,83,0.948979591836735,0.908163265306122,93,79,98,86,89,79,"not used",NA,3.1,NA,NA,3.9,NA,NA,0,0,0,0,0,"high risk","high risk","high risk","high risk","low risk","high risk"
221,"Cao",2017,"european journal of clinical microbiology and infectious diseases","Efficacy and safety of morinidazole in pelvic inflammatory disease: results of a multicenter, double-blind, randomized trial","clinical response","percentage","PP",1,0,0,0,1,0,1,1,1,0,168,157,0.946428571428571,0.9,159,154,170,149,153,148,"two sided 95%",10,5.8,-4.1,5.1,0.07,-3.8,4,0,0,0,0,0,"low risk","low risk","low risk","low risk","low risk","high risk"
222,"Koksal",2013,"acta gastro-enterologica belgica","Twice a day quadruple therapy for the first-line treatment of Helicobacter pylori in an area with a high prevalence of background antibiotic resistance","eradication","percentage","both",1,0,0,0,0,0,1,0,0,0,45,33,0.844444444444444,0.977777777777778,38,33,45,40,44,40,"two sided 95%",10,-15.6,NA,NA,-3.3,NA,NA,0,0,0,0,0,"unclear","unclear","high risk","high risk","high risk","high risk"
223,"Molton",2019,"clinical infectious diseases","Oral vs Intravenous Antibiotics for Patients With Klebsiella pneumoniae Liver Abscess: A Randomized, Controlled Noninferiority Study","clinical cure at 12 weeks","percentage","ITT.or.mITT",1,0,0,0,1,0,1,0,0,0,74,71,0.797297297297297,0.871794871794872,59,58,78,72,68,66,"two sided 95%",12,3.6,-4.9,12.8,1.2,-6.4,9,1,0,0,1,0,"low risk","high risk","high risk","high risk","low risk","low risk"
224,"Cranendonk",2019,"clinical microbiology and infection","Antibiotic treatment for 6 days versus 12 days in patients with severe cellulitis: a multicentre randomized, double-blind, placebo-controlled, non-inferiority trial","clinical cure by day 14 without relapse","percentage","ITT.or.mITT",1,0,0,0,1,1,1,1,0,0,73,36,0.904109589041096,0.868421052631579,66,34,76,38,66,29,"two sided 95%",10,0.7,-15,16.3,-7.6,-23.8,9.2,1,1,0,0,0,"low risk","low risk","high risk","low risk","low risk","low risk"
225,"File",2019,"clinical infectious diseases","Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial","clinical response","percentage","ITT.or.mITT",0,1,0,0,1,1,1,1,0,0,273,223,0.864468864468865,0.897435897435897,236,205,273,230,245,219,"two sided 95%",10,-2.6,-8.9,3.9,-2.5,-8.4,3.4,0,0,0,0,0,"unclear","unclear","low risk","low risk","low risk","low risk"
226,"Clarke",2019,"open forum infectious diseases","Lessons Learned From a Randomized Controlled Trial of Short-Course Intravenous Antibiotic Therapy for Erysipelas and Cellulitis of the Lower Limb (Switch Trial)","resolution","percentage","ITT.or.mITT",1,0,0,0,1,0,0,0,1,0,39,31,0.974358974358974,0.951219512195122,38,31,41,35,39,35,"two sided 95%",10,-5.8,-22.5,10.7,-8.2,-23.7,7.4,0,0,0,0,0,"unclear","unclear","high risk","high risk","low risk","low risk"
227,"Yahav",2019,"clinical infectious diseases","Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial","composite of mortality, complications, readmissions, prolonged hospital stay","percentage","ITT.or.mITT",1,0,0,0,1,0,1,0,0,0,306,166,0.915032679738562,0.926174496644295,280,152,298,154,276,144,"two sided 95%",10,2.6,-5.3,10.5,2.1,-6.2,10.4,0,0,0,0,0,"low risk","low risk","high risk","high risk","low risk","low risk"
23,"Dalen",2017,"emergency medicine journal","Intravenous cefazolin plus oral probenecid versus oral cephalexin for the treatment of skin and soft tissue infections: a double-blind, non-inferiority, randomised controlled trial","clinical failure","percentage","PP",0,1,0,0,1,0,1,1,1,0,101,92,0.95049504950495,0.970588235294118,96,92,102,93,99,93,"two sided 90%",10,0.1,-6.7,6.9,-1.9,-3.7,7.6,1,1,0,0,0,"low risk","unclear","low risk","low risk","low risk","low risk"
230,"Muntenu",2017,"plos one","Efficacy and safety of sequential versus quadruple therapy as second-line treatment for helicobacter pylori infection A randomized controlled trial","eradication","percentage","ITT.or.mITT",0,0,0,1,1,0,1,1,0,0,47,23,0.829787234042553,0.617021276595745,39,23,47,20,29,20,"two sided 95%",15,6.4,-14,27,-10,NA,NA,1,1,0,0,0,"low risk","unclear","high risk","high risk","low risk","high risk"
231,"Tancawan",2015,"international journal of dentistry","Amoxicillin/Clavulanic Acid for the Treatment of Odontogenic Infections: A Randomised Study Comparing Efficacy and Tolerability versus Clindamycin","clinical success","percentage","PP",1,0,1,0,0,0,1,1,0,0,234,195,0.952991452991453,0.966244725738397,223,197,237,203,229,205,"two sided 95%",10,-2.3,-9,4.3,-1.5,-7.7,4.7,1,1,0,0,0,"unclear","unclear","high risk","high risk","low risk","low risk"
232,"Fomin",2005,"international journal of surgery","Tigecycline is efficacious in the treatment of complicated intra-abdominal infections","clinical cure","percentage","both",0,1,1,1,1,1,1,1,0,1,322,279,0.822981366459627,0.808777429467085,265,242,319,270,258,232,"two sided 95%",15,2,-3.7,7.5,1.4,-4,6.8,0,0,0,0,0,"low risk","low risk","low risk","low risk","high risk","low risk"
234,"O'Riordan",2019,"new england journal of medicine","Omadacycline for Acute Bacterial Skin and Skin-Structure Infections","early clinical response","percentage","ITT.or.mITT",0,1,0,0,1,1,0,1,0,0,316,268,0.943037974683544,0.945337620578778,298,276,311,266,294,278,"two sided 95%",10,-0.7,-6.3,4.9,-1.9,-6.1,2.1,1,1,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
235,"Graham",2002,"clinical infectious diseases","Ertapenem Once Daily Versus Piperacillin-Tazobactam 4 Times per Day for Treatment of Complicated Skin and Skin-Structure Infections in Adults: Results of a Prospective, Randomized, Double-Blind Multicenter Study","clinical response","percentage",NA,0,1,0,0,0,0,1,1,0,0,274,191,0.675182481751825,0.654135338345865,185,152,266,196,174,147,"two sided 95%",15,-3.6,-11.6,4.4,-2,-10.2,6.2,1,1,0,0,0,"unclear","unclear","low risk","low risk","high risk","low risk"
236,"Lipsky",2005,"lancet","Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial","favorable clinical response","percentage","PP",0,1,0,0,1,1,1,1,0,1,289,206,0.782006920415225,0.768421052631579,226,213,285,188,219,202,"two sided 95%",15,5,-2.6,12.5,1.9,-2.9,6.9,1,1,0,0,0,"low risk","high risk","high risk","low risk","low risk","low risk"
237,"Ortiz-Ruiz",2002,"clinical infectious diseases","A Study Evaluating the Efficacy, Safety, and Tolerability of Ertapenem versus Ceftriaxone for the Treatment of Community-Acquired Pneumonia in Adults","favorable clinical response","percentage","PP",0,1,0,0,1,1,1,1,0,0,236,201,0.771186440677966,0.804,182,168,250,212,201,183,"two sided 95%",10,0.1,NA,NA,1,-4.9,7,0,0,0,0,0,"unclear","unclear","high risk","low risk","high risk","high risk"
238,"Vetter",2002,"clinical therapeutics","A Prospective, Randomized, Double-Blind Multicenter Comparison of Parenteral Ertapenem and Ceftriaxone for the Treatment of Hospitalized Adults with Community-Acquired Pneumonia","clinical response","percentage","PP",0,1,0,0,0,1,1,1,0,0,227,196,0.801762114537445,0.768595041322314,182,167,121,105,93,87,"two sided 95%",10,-0.5,NA,NA,-1.5,-8.6,5.7,0,0,0,0,0,"low risk","unclear","high risk","low risk","high risk","high risk"
239,"Jimenez-Cruz",2002,"urology","A prospective, multicenter, randomized, double-blind study comparing Ertapenem and Ceftriaxone folowed by appropriate oral therapy for complicated urinary tract infections in adults","microbiologic eradication","percentage","PP",0,1,1,1,1,0,1,1,0,0,131,113,0.740458015267176,0.746478873239437,97,83,71,58,53,45,"two sided 95%",20,4.3,-7.5,16.1,0.6,-12.9,14.1,0,0,0,0,0,"unclear","unclear","high risk","low risk","high risk","low risk"
240,"Tomera",2002,"antimicrobial agents and chemotherapy","Ertapenem versus Ceftriaxone Followed by Appropriate Oral Therapy for Treatment of Complicated Urinary Tract Infections in Adults: Results of a Prospective, Randomized, Double-Blind Multicenter Study","microbiologic eradication","percentage","PP",0,1,0,1,1,0,0,1,0,1,219,203,0.726027397260274,0.706611570247934,159,146,242,220,171,159,"two sided 95%",10,1.4,-4,6.9,-1.2,-7.6,5.1,0,0,0,0,0,"low risk","unclear","high risk","low risk","high risk","low risk"
241,"Roy",2003,"infectious diseases in obstetrics and gynecology","Ertapenem once a day versus piperacillin_tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study","clinical response","percentage","PP",0,1,1,0,1,0,0,1,0,0,211,181,0.772511848341232,0.801047120418848,163,153,191,168,153,140,"two sided 95%",10,-2.1,-9.2,5,2.4,-4,8.8,1,1,0,0,0,"low risk","unclear","low risk","low risk","low risk","low risk"
242,"Tellier",2004,"journal of antimicrobial chemotherapy","Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia","clinical cure","percentage","PP",0,1,0,0,0,0,1,0,0,0,191,157,0.842931937172775,0.806629834254144,161,143,181,147,146,134,"two sided 95%",15,1,NA,NA,-3,-10.2,4.3,0,0,0,0,0,"unclear","unclear","low risk","low risk","high risk","high risk"
242,"Tellier",2004,"journal of antimicrobial chemotherapy","Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia","clinical cure","percentage","PP",0,1,0,0,0,0,1,0,0,0,187,154,0.850267379679144,0.806629834254144,159,142,181,147,146,134,"two sided 95%",15,1.2,NA,NA,-2.5,-9.7,4.7,0,0,0,0,0,"unclear","unclear","low risk","low risk","high risk","high risk"
243,"Dunbar",2004,"clinical therapeutics","Efficacy and tolerability of once-daily oral Telithromycin compared with Clarithromycin for the treatment of community-acquired pneumonia in adults","clinical cure","percentage","PP",0,1,0,0,1,0,1,1,0,0,204,161,0.794117647058823,0.735849056603774,162,143,212,171,156,138,"two sided 95%",15,-1.7,-9.9,6.5,-0.2,-7.8,7.5,1,1,0,0,0,"high risk","unclear","low risk","low risk","low risk","low risk"
244,"Stryjewski",2008,"clinical infectious diseases","Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin-Structure Infections Caused by Gram-Positive Organisms","clinical response","percentage","PP",0,1,1,0,1,1,1,1,0,1,928,710,0.802801724137931,0.792332268370607,745,658,939,697,744,648,"two sided 95%",10,2.3,-1.6,6.2,1.2,-2.1,4.6,0,0,0,0,0,"unclear","low risk","low risk","low risk","low risk","low risk"
245,"Naber",2009,"antimicrobial agents and chemotherapy","Intravenous Doripenem at 500 Milligrams versus Levofloxacin at 250 Milligrams, with an Option To Switch to Oral Therapy, for Treatment of Complicated Lower Urinary Tract Infection and Pyelonephritis","microbiologic cure","percentage","both",0,1,1,0,1,1,1,1,0,0,327,259,0.856269113149847,0.825545171339564,280,230,321,251,265,221,"two sided 95%",10,1,-5.6,7.6,-1.3,-8,5.5,1,1,0,0,0,"low risk","low risk","high risk","low risk","high risk","low risk"
246,"Breedt",2005,"antimicrobial agents and chemotherapy","Safety and Efficacy of Tigecycline in Treatment of Skin and Skin Structure Infections: Results of a Double-Blind Phase 3 Comparison Study with Vancomycin-Aztreonam","clinical response","percentage","both",0,1,1,0,1,1,0,1,0,1,261,220,0.854406130268199,0.822393822393822,223,200,259,225,213,201,"two sided 95%",15,-2.6,-9,3.8,-4.7,-10.2,0.8,0,0,0,0,0,"unclear","unclear","low risk","low risk","low risk","low risk"
26,"Bowen",2014,"lancet","Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled, non-inferiority trial","treatment success based on photo","percentage","ITT.or.mITT",0,1,0,0,1,1,1,1,1,0,334,283,0.92814371257485,0.935897435897436,310,264,156,133,146,124,"two sided 95%",10,-0.5,-7.3,6.2,0.2,-5.6,6.1,0,0,0,0,0,"low risk","low risk","high risk","low risk","low risk","low risk"
27,"Chen",2016,"american journal of gastroenterology","Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy","eradication rate","percentage",NA,1,1,0,1,1,1,1,1,0,0,156,138,0.91025641025641,0.82051282051282,142,133,156,136,128,122,"two sided 95%",10,1.3,-4.8,7.4,-1.7,-6.2,2.9,1,1,0,0,0,"low risk","low risk","high risk","low risk","high risk","low risk"
29,"Zhong",2015,"lancet infectious diseases","Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial","clinical cure","percentage","PP",0,1,0,0,1,1,0,1,1,0,381,305,0.677165354330709,0.628272251308901,258,217,382,256,240,178,"two sided 95%",10,13,6.8,19.2,9.9,2.8,17.1,0,0,0,0,0,"low risk","unclear","low risk","low risk","high risk","low risk"
30,"Stahlgren",2019,"british medical journal","Penicillin V four times daily for five days versus three times daily for 10 days in patients with pharyngotonsillitis caused by group A streptococci: randomised controlled, open label, non-inferiority study","clinical cure","percentage","PP",0,1,0,0,1,1,1,1,1,0,212,190,0.952830188679245,0.928571428571429,202,181,210,197,195,182,"two sided 95%",10,-4.2,-9.9,1.5,-3.7,-9.7,2.2,1,0,0,0,1,"low risk","low risk","high risk","high risk","low risk","low risk"
31,"Chandra",2008,"surgical infections","Cefoperazone-Sulbactam for treatment of intra-abdominal infections: Results from a randomized, parallel group study in India","clinical success","percentage",NA,0,1,0,0,1,1,1,1,0,0,154,134,0.883116883116883,0.868421052631579,136,125,152,118,132,108,"two sided 95%",12.5,10.1,2,18.3,10.1,2.1,18.1,0,0,0,0,0,"unclear","unclear","high risk","high risk","low risk","low risk"
33,"Pullman",2017,"journal of antimicrobial chemotherapy","Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study","early clinical response","percentage","ITT.or.mITT",1,0,0,0,1,1,1,0,0,0,331,259,0.88821752265861,0.90273556231003,294,250,329,266,297,257,"two sided 95%",10,-2.6,-8.78,3.57,-1.5,-7.2,4.18,1,1,0,0,0,"low risk","low risk","low risk","low risk","high risk","low risk"
34,"Wagenlehner",2015,"lancet","Ceftolozane-tazobactam compared with levofl oxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","composite cure","percentage","ITT.or.mITT",0,1,0,0,1,1,1,1,0,0,398,306,0.85678391959799,0.878109452736318,341,284,402,275,353,266,"two sided 95%",10,8.5,2.3,14.6,8,2,14,1,1,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
38,"Gerding",2019,"lancet infectious diseases","Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials","clinical cure","percentage","both",0,1,0,0,0,0,0,0,0,0,302,253,0.933774834437086,0.905660377358491,282,247,318,271,288,264,"two sided 95%",10,-1.4,-7.2,4.3,-4.1,-9.2,1,1,1,0,0,0,"low risk","unclear","low risk","low risk","low risk","low risk"
38,"Gerding",2019,"lancet infectious diseases","Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials","clinical cure","percentage","both",0,1,0,0,0,0,0,0,0,0,290,235,0.851724137931035,0.86046511627907,247,214,301,258,259,237,"two sided 95%",10,-4.1,-9.2,1,-4.9,-10.4,0.6,1,1,0,0,0,"low risk","unclear","low risk","low risk","low risk","low risk"
39,"Paul",2015,"british medical journal","Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial","clinical failure","percentage","ITT.or.mITT",1,0,0,0,0,0,1,0,0,0,135,84,0.814814814814815,0.82051282051282,110,73,117,85,96,70,"two sided 95%",15,-11,-21.5,1.2,7,NA,NA,0,0,0,0,0,"low risk","low risk","high risk","high risk","low risk","low risk"
4,"Chosidow",2005,"dermatology","Cloxacillin versus Pristinamycin for Superficial Pyodermas: A Randomized, Open-Label, Non-Inferiority Study","clinical cure","percentage","both",1,0,0,0,0,1,0,0,0,0,171,138,0.947368421052632,0.914110429447853,162,133,163,135,149,127,"two sided 95%",15,-2.1,-10.4,6.2,-3.1,-11.3,5.1,0,0,0,0,0,"low risk","low risk","high risk","high risk","low risk","low risk"
40,"Nathan",2005,"lancet","Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study","treatment failure","percentage","both",0,0,0,0,1,1,0,0,0,1,247,225,0.647773279352227,0.578125,160,152,256,234,148,140,"two sided 90%",10,-0.3,-4.5,3.8,0.4,-3.8,4.6,0,0,0,0,0,"low risk","low risk","high risk","high risk","low risk","high risk"
41,"Rhee",2015,"international journal of copd","Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial","clinical cure","percentage","PP",0,1,0,0,1,1,0,1,1,0,175,135,0.817142857142857,0.784431137724551,143,124,167,129,131,113,"two sided 95%",10,-0.1,-9,8.8,0.4,-7.7,8.6,0,0,0,0,0,"low risk","unclear","low risk","low risk","low risk","low risk"
42,"Llor",2017,"atencion primaria","Efficacy of high doses of penicillin versus amoxicillin in the treatment of uncomplicated community acquired pneumonia in adults. A non-inferiority controlled clinical trial","clinical cure","percentage",NA,0,1,1,0,1,1,0,0,1,1,14,10,0.785714285714286,1,11,10,25,25,25,25,"two sided 95%",15,-28.6,-58.1,-7.3,-9.1,-41.3,6.4,0,0,0,0,0,"low risk","unclear","low risk","low risk","low risk","low risk"
43,"Xu",2016,"journal of antimicrobial chemotherapy","Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial","clinical response","percentage","both",0,1,1,0,1,1,1,1,0,1,267,237,0.820224719101124,0.842105263157895,219,205,266,241,224,218,"two sided 95%",15,-1.9,-7.3,3.3,-3.8,-8.3,0,1,1,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
45,"Dryden",2016,"journal of antimicrobial chemotherapy","A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities","clinical cure","percentage","both",0,1,0,0,1,1,0,0,0,1,506,396,0.780632411067194,0.827450980392157,395,342,255,202,211,180,"two sided 95%",10,-0.95,-6.9,5.41,1.27,-4.32,7.48,0,0,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
46,"Ren",2017,"international urology nephrology","Treatment of complicated urinary tract infection and acute pyelonephritis by short_course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open_label, randomized, controlled, multicenter, non_inferiority clinical trial","clinical success","percentage",NA,0,1,0,0,1,1,1,1,0,0,159,142,0.911949685534591,0.917721518987342,145,131,158,142,145,135,"two sided 95%",15,0.56,-6.16,7.29,2.76,-3.58,9.09,1,0,0,0,1,"unclear","unclear","high risk","high risk","high risk","low risk"
47,"Heystek",2009,"international journal of std & aids","A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease","clinical success","percentage","PP",0,1,0,0,1,1,1,0,0,0,343,264,0.676384839650146,0.619631901840491,232,224,326,250,202,198,"two sided 95%",10,0.3,-5.8,6.9,1.4,-4.5,1.6,1,1,0,0,0,"unclear","unclear","low risk","low risk","high risk","low risk"
48,"Bocquet",2012,"pediatrics","Randomized Trial of Oral Versus Sequential IV/Oral Antibiotic for Acute Pyelonephritis in Children","renal scarring","percentage",NA,0,1,1,1,1,1,0,1,1,0,61,36,0.852459016393443,0.758620689655172,52,36,58,32,44,32,"two sided 95%",10,3.8,-13.9,21.6,-3.5,-21.7,14.7,0,0,0,0,0,"low risk","unclear","high risk","high risk","high risk","high risk"
5,"Harbarth",2015,"journal of antimicrobial chemotherapy","Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection","clinical resolution","percentage",NA,1,0,0,0,1,0,1,1,0,0,75,59,0.786666666666667,0.88,59,52,75,56,66,54,"two sided 95%",20,4,-9.7,17.6,6.3,-6.8,19.2,1,1,0,0,0,"low risk","low risk","high risk","high risk","high risk","low risk"
50,"Bartacek",2009,"international journal of tuberculous lung disease","Comparison of a four-drug fi xed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis","microbiologic cure","percentage",NA,1,0,0,0,1,1,1,0,0,1,582,468,0.707903780068729,0.731369150779896,412,404,577,477,422,416,"two sided 95%",10,-2.26,-6.72,2.21,-0.51,-2.27,1.23,1,1,0,0,0,"low risk","low risk","high risk","high risk","high risk","low risk"
52,"Torres",2018,"lancet infectious diseases","Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","clinical cure","percentage","both",0,0,1,0,1,1,1,1,0,0,401,245,0.640897755610973,0.922693266832918,257,199,401,270,370,211,"two sided 95%",12.5,-4.2,-10.76,2.46,-0.7,-7.86,6.39,0,0,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
53,"Gyssens",2011,"journal of antimicrobial chemotherapy","A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections","clnical success","percentage","PP",0,1,0,0,1,1,1,1,0,0,426,350,0.847417840375587,0.814323607427056,361,320,377,350,307,275,"two sided 95%",10,1.25,-3.8,6.3,-0.72,-5.3,3.9,0,0,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
54,"Zhao",2016,"journal of thoracic disease","A randomized, open, multicenter clinical study on the short course of intravenous infusion of 750 mg of levofloxacin and the sequential standard course of intravenous infusion/oral administration of 500 mg of levofloxacin for treatment of community-acquired pneumonia","clinical cure or improvement","percentage","ITT.or.mITT",0,1,0,1,1,1,1,1,0,0,221,202,0.941176470588235,0.964757709251101,208,195,227,214,219,210,"two sided 95%",10,-2.87,-7.64,1.9,-2.14,-6.35,2.07,0,0,0,0,0,"unclear","unclear","high risk","high risk","low risk","low risk"
55,"Tanaseanu",2009,"bmc pulmonary medicine","Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia","clinical response","percentage","both",0,1,1,0,1,1,1,1,0,0,203,170,0.70935960591133,0.68,144,128,200,163,136,116,"two sided 95%",15,2,-5.5,9.6,3.6,-4.5,11.8,0,0,0,0,0,"low risk","low risk","unclear","unclear","low risk","low risk"
56,"Towfigh",2009,"clinical microbiology and infection","A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections","clinical response","percentage","ITT.or.mITT",0,1,1,0,1,1,1,1,0,0,228,145,0.828947368421053,0.85,189,133,220,155,187,139,"two sided 95%",15,-7,-15.8,1.08,-4,-13.1,5.1,0,0,0,0,0,"low risk","unclear","high risk","high risk","low risk","low risk"
57,"Yakovlev",2006,"european journal of clinical microbiology and infectious diseases","Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit","clinical response","percentage","PP",0,1,1,0,1,0,0,1,0,1,144,101,0.645833333333333,0.698630136986301,93,80,146,109,102,89,"two sided 95%",15,4.1,-6.7,15,1.3,-9.4,11.8,0,1,0,0,0,"low risk","unclear","low risk","low risk","low risk","low risk"
59,"Nakane",2015,"journal of infection and chemotherapy","Cefozopran, meropenem, or imipenemecilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial","clinical response","percentage","PP",0,0,1,1,1,1,1,0,0,1,95,54,0.947368421052632,0.913978494623656,90,54,93,56,85,56,"two sided 95%",10,NA,NA,NA,NA,NA,NA,0,0,0,0,0,"unclear","unclear","high risk","high risk","low risk","high risk"
59,"Nakane",2015,"journal of infection and chemotherapy","Cefozopran, meropenem, or imipenemecilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial","clinical response","percentage","PP",0,0,1,1,1,1,1,0,0,1,94,63,0.936170212765957,0.913978494623656,88,63,93,56,85,56,"two sided 95%",10,NA,NA,NA,NA,NA,NA,0,0,0,0,0,"unclear","unclear","high risk","high risk","low risk","high risk"
59,"Nakane",2015,"journal of infection and chemotherapy","Cefozopran, meropenem, or imipenemecilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial","clinical response","percentage","PP",0,0,1,1,1,1,1,0,0,1,94,60,0.978723404255319,0.913978494623656,92,60,93,56,85,56,"two sided 95%",10,NA,NA,NA,NA,NA,NA,0,0,0,0,0,"unclear","unclear","high risk","high risk","low risk","high risk"
6,"Brack",2012,"pediatric blood cancer","First-Day Step-Down to Oral Outpatient Treatment Versus Continued Standard Treatment in Children With Cancer and Low-Risk Fever in Neutropenia. A Randomized Controlled Trial Within the Multicenter SPOG 2003 FN Study","resolution of infection without recurrence or modification of antimicrobial therapy or adverse effects","percentage","ITT.or.mITT",1,0,0,0,1,1,0,0,0,0,27,23,0.925925925925926,0.911764705882353,25,23,34,26,31,23,"one sided 95%",10,8.7,-9.4,NA,18,0.4,NA,0,0,0,0,0,"unclear","low risk","high risk","high risk","low risk","low risk"
60,"Waele",2013,"international journal of antimicrobial agents","Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study","clinical success","percentage","PP",0,1,0,1,1,1,1,1,1,0,408,334,0.862745098039216,0.88974358974359,352,315,390,339,347,324,"two sided 95%",10,-5,-9.9,0,-3.9,-7.9,0.4,0,0,0,0,0,"unclear","low risk","low risk","low risk","high risk","high risk"
61,"Namias",2007,"surgical infections","Randomized, Multicenter, Double-Blind Study of Efficacy, Safety, and Tolerability of Intravenous Ertapenem versus Piperacillin/Tazobactam in Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults","clinical cure","percentage","PP",0,1,1,0,1,1,1,1,0,1,189,119,0.650793650793651,0.577540106951872,123,122,187,114,108,107,"two sided 95%",15,2.3,-7.5,12,0.3,-9.6,10.5,1,1,0,0,0,"unclear","unclear","low risk","low risk","high risk","low risk"
62,"Lora Tamayo",2016,"international journal of antimicrobial agents","Short- versus long-duration levofloxacin plus rifampicin for acute staphylococcal prosthetic joint infection managed with implant retention: a randomised clinical trial","clinical cure","percentage","both",1,0,0,0,1,1,1,1,0,0,30,22,0.8,0.606060606060606,24,22,33,19,20,19,"two sided 95%",15,15.7,-7.8,39.2,-3.3,-18.3,11.7,0,0,0,0,0,"unclear","unclear","high risk","high risk","high risk","low risk"
63,"Ibrahim",2019,"lancet infectious diseases","Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial","treatment failure","percentage",NA,1,0,0,0,1,1,0,0,1,0,93,91,0.956989247311828,0.957894736842105,89,88,95,88,91,84,"two sided 95%",15,5.3,-0.8,11.3,6.5,0.7,12.4,0,0,0,0,0,"low risk","unclear","high risk","high risk","low risk","low risk"
66,"Solomkin",2009,"international journal of antimicrobial agents","Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections","clinical success","percentage","PP",0,0,0,0,1,0,1,1,0,0,180,157,0.966666666666667,0.94475138121547,174,157,181,165,171,165,"two sided 95%",15,-4,-10.7,1.9,-6.3,-11.7,-1.7,0,0,0,0,0,"unclear","unclear","low risk","low risk","low risk","low risk"
69,"Lv",2017,"antimicrobial agents and chemotherapy","Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection","early clinical response","percentage","ITT.or.mITT",1,1,1,0,1,1,0,1,0,0,300,226,0.73,0.775167785234899,219,198,298,238,231,216,"two sided 95%",10,-4.6,-11.2,2.2,-2.1,-7.4,3.2,1,1,0,0,0,"unclear","unclear","low risk","low risk","high risk","low risk"
7,"Goyal",2018,"lancet","Amoxicillin_clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial","resolution of exacerbation based on phone interview","percentage","PP",1,0,0,0,1,1,1,0,0,0,82,63,0.890243902439024,0.896907216494845,73,61,97,75,87,73,"two sided 95%",20,-0.5,-12.9,11.9,-0.3,-11.8,11.1,1,1,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
70,"Yuan",2018,"journal of microbiology, immunology and infection","Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial","clinical cure","percentage","ITT.or.mITT",0,1,1,1,1,1,1,1,0,0,328,300,0.929878048780488,0.91875,305,290,160,143,147,138,"two sided 95%",10,0.9,-3.8,5.5,1.2,-3.4,5.8,1,1,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
72,"Liou",2018,"journal of antimicrobial chemotherapy","14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial","eradication","percentage","ITT.or.mITT",1,0,0,0,1,1,1,1,0,0,310,283,0.958064516129032,0.935483870967742,297,279,310,284,290,277,"two sided 95%",5,-0.3,-4.7,4.4,-1.6,-5.2,2,0,0,0,0,0,"low risk","low risk","high risk","high risk","low risk","low risk"
73,"Aseffa",2016,"plos one","Efficacy and Safety of �Fixed Dose� versus �Loose� Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TBBurden African Countries: A Randomized Controlled Trial","microbiologic cure","percentage","ITT.or.mITT",0,1,1,0,1,0,1,1,0,0,459,398,0.790849673202614,0.765591397849462,363,359,465,396,356,345,"one sided 95%",4,1.55,-2.22,5.32,2,0.13,3.8,1,1,0,0,0,"low risk","low risk","high risk","low risk","high risk","low risk"
78,"File",2001,"journal of antimicrobial chemotherapy","Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin","clinical success","percentage","PP",1,0,0,0,0,0,1,0,0,0,290,254,0.744827586206897,0.736654804270463,216,203,281,228,207,186,"two sided 95%",10,6.4,0.5,12.4,4.1,-1.1,9.3,0,0,0,0,0,"unclear","unclear","low risk","low risk","low risk","low risk"
79,"Harris",2018,"jama","Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial","mortality","percentage","ITT.or.mITT",0,1,0,0,1,1,1,0,1,0,187,164,0.909090909090909,0.973821989528796,170,152,191,184,186,179,"one sided 97.5%",5,-8.6,-14.5,NA,-6.8,-12.8,NA,1,0,0,1,0,"low risk","low risk","high risk","high risk","low risk","low risk"
8,"Bernard",2002,"british medical journal","Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non_inferiority, open trial","clinical cure","percentage",NA,1,0,0,0,1,1,1,1,0,0,138,90,0.739130434782609,0.68,102,83,150,79,102,68,"not used",10,12,1.7,NA,14.7,3.3,NA,0,0,0,0,0,"low risk","low risk","high risk","high risk","low risk","low risk"
82,"Aliberti",2017,"pulmonary pharmacology & therapeutics","Individualizing duration of antibiotic therapy in community-acquired pneumonia","early failure","percentage","ITT.or.mITT",1,0,0,0,0,0,1,0,0,0,125,111,0.648,1,81,75,135,125,135,125,"one sided 95%",5,-3.8,NA,NA,0,NA,NA,0,0,0,0,0,"unclear","low risk","high risk","high risk","high risk","high risk"
83,"Giusti",2016,"journal of chronic obstructive pulmonary disease","Prulifloxacin vs Levofloxacin for Exacerbation of COPD after Failure of Other Antibiotics","therapeutic success","percentage","both",1,0,0,0,1,0,1,1,0,0,128,119,0.9609375,0.953846153846154,123,116,130,126,124,123,"not used",15,3.7,NA,NA,4.5,NA,NA,0,0,0,0,0,"unclear","unclear","low risk","high risk","high risk","high risk"
87,"Oliva",2005,"bmc infectious diseases","A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections","clinical cure","percentage","both",0,1,1,0,1,1,1,1,0,0,309,227,0.799352750809062,0.817307692307692,247,199,312,244,255,210,"two sided 95%",15,-4.3,-11,2.5,-1.7,-8.4,5.1,0,0,0,0,0,"unclear","unclear","low risk","low risk","low risk","low risk"
88,"Judlin",2010,"general gynaecology","Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study","clinical response","percentage","PP",1,0,0,0,1,1,1,1,1,0,228,163,0.850877192982456,0.818965517241379,194,152,232,171,190,155,"two sided 95%",15,-2.2,-10.1,5.9,-3.2,-10.7,4.9,0,0,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
89,"Zhang",2015,"gut","Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy","eradication","percentage",NA,1,1,0,1,0,0,1,0,0,0,108,96,0.898148148148148,0.91588785046729,97,94,107,95,98,93,"two sided 95%",10,0.1,-7,7.2,2,-2.7,6.7,1,1,0,0,0,"low risk","low risk","high risk","high risk","low risk","low risk"
9,"Liu",2019,"antimicrobial agents and chemotherapy","Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia","clinical success","percentage",NA,0,0,0,0,1,0,1,1,0,0,71,62,0.929577464788732,0.975903614457831,66,54,83,70,81,64,"two sided 95%",20,3,-9,15,2.8,-11.4,17,0,0,0,0,0,"unclear","low risk","high risk","low risk","high risk","high risk"
90,"Ross",2006,"sexually transmitted infections","Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial","clinical resolution","percentage","PP",0,1,0,1,1,1,1,1,1,0,378,286,0.727513227513228,0.796143250688705,275,248,363,300,289,262,"two sided 95%",10,-6.9,-12.3,-0.9,-0.5,-5.7,4,1,1,0,0,0,"unclear","unclear","low risk","low risk","low risk","low risk"
92,"Nicholson",2012,"international journal of antimicrobial agents","A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","clinical cure","percentage","both",1,0,0,0,1,1,1,1,0,0,314,240,0.735668789808917,0.734567901234568,231,200,324,257,238,208,"two sided 95%",10,-2.9,-9.3,3.6,-0.8,-6.9,5.3,0,0,0,0,0,"unclear","unclear","unclear","unclear","low risk","low risk"
94,"Wilson",2012,"european respiratory journal","Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results","clinical failure","percentage","PP",0,1,0,1,1,1,1,1,0,0,677,539,0.794682422451994,0.767407407407407,538,427,675,529,518,404,"two sided 95%",6,1.2,-3.03,5.5,1.4,-3.83,5.89,1,1,0,0,0,"low risk","low risk","low risk","low risk","low risk","low risk"
97,"Rob",2019,"clinical microbiology and infection","Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial","microbiologic eradication","percentage",NA,1,0,0,0,1,1,0,1,0,0,73,72,0.986301369863014,0.986111111111111,72,72,72,71,71,71,"two sided 95%",7,0.02,-6.1,6.2,0,-5.1,5.1,0,0,0,0,0,"low risk","low risk","high risk","high risk","low risk","low risk"
99,"Petitpretz",2007,"international journal of antimicrobial agents","Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval","clinical cure","percentage","PP",0,1,1,0,1,1,0,0,0,0,289,273,0.896193771626298,0.871621621621622,259,245,296,273,258,242,"two sided 95%",10,2.3,-1.8,6.2,0.8,-3.2,4.8,0,0,0,0,0,"unclear","unclear","high risk","high risk","high risk","low risk"